Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, Matthew H Taylor, Martin Schuler, Viola W Zhu, Julien Hadoux, Giuseppe Curigliano, Lori Wirth, Justin F Gainor, Guzman Alonso, Douglas R Adkins, Yann Godbert, Myung-Ju Ahn, Philippe A Cassier, Byoung Chul Cho, Chia-Chi Lin, Alena Zalutskaya, Teresa Barata, Peter Trask, Astrid Scalori, Walter Bordogna, Sebastian Heinzmann, Marcia Brose
BACKGROUND: RET alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET-altered thyroid cancer. We present an updated analysis with more patients and longer follow-up. METHODS: Adult patients with advanced/metastatic RET-mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer who initiated oral pralsetinib at 400mg once daily, were included...
November 27, 2023: Thyroid: Official Journal of the American Thyroid Association